Last10K.com

Oncotelic Therapeutics, Inc. (OTLC) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Oncotelic Therapeutics, Inc.

HISTORY TOOLS
CIK: 908259 Ticker: OTLC
Cover - USD ($)
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Mar. 20, 2022
Jun. 30, 2021
Cover [Abstract]    
Document Type10-K   
Amendment Flagfalse   
Document Annual Reporttrue   
Document Transition Reportfalse   
Document Period End DateDec. 31, 2021   
Document Fiscal Period FocusFY   
Document Fiscal Year Focus2021   
Current Fiscal Year End Date--12-31   
Entity File Number0-21990   
Entity Registrant NameOncotelicTherapeutics, Inc.   
Entity Central Index Key0000908259   
Entity Tax Identification Number13-3679168   
Entity Incorporation, State or Country CodeDE   
Entity Address, Address Line One29397 Agoura Road   
Entity Address, Address Line TwoSuite 107   
Entity Address, City or TownAgoura Hills   
Entity Address, State or ProvinceCA   
Entity Address, Postal Zip Code91301   
City Area Code(650)   
Local Phone Number635-7000   
Title of 12(b) SecurityNone   
Entity Well-Known Seasoned IssuerNo   
Entity Voluntary FilersNo   
Entity Current Reporting StatusYes   
Entity Interactive Data CurrentYes   
Entity Filer CategoryNon-accelerated Filer   
Entity Small Businesstrue   
Entity Emerging Growth Companyfalse   
Entity Shell Companyfalse   
Entity Public Float   $ 34,739,000
Entity Common Stock, Shares Outstanding  378,630,104 
Documents Incorporated by Reference [Text Block]None.   
ICFR Auditor Attestation Flagfalse   
Auditor Firm ID468   
Auditor NameRose, Snyder & Jacobs LLPBAKER TILLY US, LLP  
Auditor LocationEncino, CALos Angeles, California  

View differences made from one year to another to evaluate Oncotelic Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncotelic Therapeutics, Inc..

Continue

Assess how Oncotelic Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Oncotelic Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statement Of Stockholders' Equity
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (Tables)
Acquisitions
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Convertible Debentures, Notes And Other Debt
Convertible Debentures, Notes And Other Debt (Details Narrative)
Convertible Debentures, Notes And Other Debt (Tables)
Description Of Business And Basis Of Presentation
Description Of Business And Basis Of Presentation (Details Narrative)
Equity Purchase Agreement And Registration Rights Agreement
Equity Purchase Agreement And Registration Rights Agreement (Details Narrative)
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Details Narrative)
Goodwill And Intangible Assets (Tables)
Income Taxes
Income Taxes (Details Narrative)
Income Taxes (Tables)
Private Placement And Jh Darbie Financing
Private Placement And Jh Darbie Financing (Details Narrative)
Private Placement And Jh Darbie Financing (Tables)
Related Party Transactions
Related Party Transactions (Details Narrative)
Related Party Transactions (Tables)
Schedule Of Accounts Payable And Accrued Expenses (Details)
Schedule Of Amortization Of Expense For Intangible Assets (Details)
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)
Schedule Of Black Scholes Valuation Allowance Model (Details)
Schedule Of Compensation Based Stock Option Activity (Details)
Schedule Of Components Of Net Deferred Tax Assets And Liabilities (Details)
Schedule Of Convertible Debentures (Details)
Schedule Of Convertible Note (Details)
Schedule Of Convertible Notes (Details)
Schedule Of Fair Value Warrants Estimated Using Black Scholes Valuation Model (Details)
Schedule Of Funds Received Under The Subscription Agreement (Details)
Schedule Of Intangible Assets (Details)
Schedule Of Options To Purchase Shares Of Common Stock Outstanding And Exercisable (Details)
Schedule Of Related Party License Agreement (Details)
Schedule Of Short-Term Loans (Details)
Schedule Of Warrants Activity (Details)
Schedule Of Warrants Outstanding And Exercisable (Details)
Schedule Of Warrants Valuation Input (Details)
Stock-Based Compensation
Stock-Based Compensation (Details Narrative)
Stock-Based Compensation (Tables)
Stockholders??? Equity
Stockholders??? Equity (Details Narrative)
Subsequent Events
Subsequent Events (Details Narrative)
Summary Of Changes In Fair Value Of Derivative Liabilities (Details)
Summary Of Estimate Fair Value Of Derivative Liabilities (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details Narrative)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Ticker: OTLC
CIK: 908259
Form Type: 10-K Annual Report
Accession Number: 0001493152-22-010094
Submitted to the SEC: Fri Apr 15 2022 4:26:47 PM EST
Accepted by the SEC: Fri Apr 15 2022
Period: Friday, December 31, 2021
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/otlc/0001493152-22-010094.htm